Table 1 .

NSABP

B-39

2005–

2013

10.2

4216

54

Equiv

IBTR

IBC or DCIS; T < 3 cm, ≤ N1; R0; > 18y

Stage,

Menopausal,

ER, CTx

3DCRT, single- and multicath. BT

34/3.4; 38.5/3.85 10 × in 5-8d

50/2; 50.4/1.8; opt. Boost

26%

24%

10%

81%

n.r

29%

n.r

80%

Budapest

1998–

2004

17

258

Mean

59

Noninf

LR

IBC; T < 2 cm; N0; R0; G1-2; unifocal

None

multicath. BT

3DCRT e-

BT:36.4/5.2 BID;

e-:50/2 QD

50/2 + 

opt. 16/2

0.0%

0%

3%

N1mic

88%

n.r

3%

99%

0.8%

RAPID

02/2006–

07/2011

8.6

2135

61

Noninf

IBTR

IBC or DCIS; T < 3 cm;R0; N0; > 40y; unifocal

Age >  < 50; Histology, T >  < 1.5 cm; ER, centre

3DCRT

IMRT

38.5/3.85 BID in 5-8d

50/2; 42.5/2.66 + opt. Boost

16%

18%

0%

84%

6%

13%

55%

21%

IRMA

2007–

2019

5

3309

65

Noninf

IBTR

IDC; T < 2.5 cm; R0; > 45y; unifocal

Centre, timing

3DCRT

38.5/3.85 BID

50/2; 50.4/1.8;

45/2.5 + opt. Boost 10–16/2

n.r

0%

7%

95%

n.r

6%

74%

n.r

Barcelona

n.r

10.3

102

Mean

69

Noninf

IBTR

IBC; T < 3 cm;R0; N0; > 60y; unifocal; G 1–2

n.r

3DCRT

37.5/3.75 BID

48/2 + 

opt. Boost 10/2

0.0%

0%

0%

98%

1%

3%

57%

n.r

India

06/2011–12/2015

5

133

Mean

50

Noninf

LR

IDC, T < 4 cm, cN0, pN0-1, R0

None

3DCRT

34/3.4 BID

40/2.5 + 

opt 10–16/2

23%

0%

12%

69%

11%

65%

74%

56%

Cairo

n.r

2

91

50

n.r

IBTR

IBC; T < 3 cm;R0; N0; > 40y;unifocal; G1-3

n.r

3DCRT

38,5/3,85 QD

38.5/3.85 BID

50/2 + 

opt. Boost

n.r

0%

0%

80%

n.r

19%

n.r

n.r

Florence

03/2005–

06/2013

10.7

520

n.r

noninf

IBTR

IBC or DCIS; T < 2.5 cm; > 40y; BCS + 

None

IMRT

30/6 q.o.d

50/2 + 

opt. Boost 10/2

11.4%

11%

10%

96%

4%

7%

62%

n.r

Import

low

05/2007–

10/2010

6

1343

62

noninf

IBTR

IDC; T < 3 cm; > 50y; pN0-1

Centre

3DCRT

40/2.67 QD

40/2.67

9.7%

0%

3%

95%

4%

5%

80%

n.r

DBCG

PBI

2009–

2016

7.6

882

66

noninf

Breast

Induration

3y

IBC, T1, R0, > 60y, G1-2, HER2-, pN0

Centre,

ET

3DCRT

40/2.67 QD

40/2,67

 < 1.0%

0%

0%

100%

0%

n.r

80%

n.r

HYPAB

01/2015–01/2018

3

172

64

n.r

Cosmetic outcome

Postmen. T1-2 pN0, unicentric, R0 (5 mm), No EIC

n.r

VMAT

30/6 alternate days

40.5/2.7

48/3.2

3%

n.r

0%

100%

n.r

n.r

97%

100%

Beijing

06/2017– 01/2019

1

115

54

noninf

Grade II + Tox

45-75y, G1-2, T < 3 cm, pN0, unifocal, ER/PR + , R0 (2 mm)

None

IMRT

40/4 QD

43.5/2.9

Opt. SIB 49.5/3.3

0%

n.r

0%

100%

7%

21%

n.r

3%

ELIOT

11/2000–

12/2007

12.4

1305

n.r

noninf

IBTR

IBC; T < 2.5 cm; R0; 48-75y; unifocal

T < 1–1.4 > cm

IORT e-

21/21

50/2 + 

opt. Boost 10/2

20.9%

0%

27%

91%

3%

8%

88%

n.r

TARGIT-A

prepathology

03/2000–

06/2012

8.6

2298

Mean

63

noninf

LRFS

IDC; T < 2.5 cm; R0; > 45y; unifocal

Centre,

timing

IORT x

20/20

n.r

20%

0%

 ~ 21%

90%

15%

21%

81%

38%

TARGIT-A

postpathology

03/2000–

06/2012

9

1153

Mean

63

noninf

LRFS

IDC; T < 2.5 cm; R0; > 45y; unifocal

Centre,

timing

IORT x

20/20

n.r

6%

3%

5%

98%

6%

4%

87%

n.r

GEC

Estro

04/2004–

07/2009

10.4

1328

62

noninf

IBTR

IBC or DCIS; T < 3 cm; R0; N0; > 40y; BCS + 

Centre,

Menopausal,

stage

multicath. BT

32/4; 30.3/4.3 or PDR

50/2; 50.4/1.8; Boost opt

8.3%

5%

6%

95%

n.r

11%

90%

98%